Gregg Keaney
Senior Vice President of CMC and Product Development
Professional Overview
Gregg Keaney is a seasoned pharmaceutical executive with over 20 years of experience in drug discovery, product development, and strategic leadership. As the Senior Vice President of CMC and Product Development at Rapport Therapeutics, he is responsible for driving the company's chemistry, manufacturing, and controls (CMC) strategies, as well as overseeing the entire product development lifecycle.
Experience Summary
Current Role
In his current position, Gregg leads a team of cross-functional experts to advance Rapport's innovative therapeutics through the development pipeline. He is instrumental in establishing robust CMC processes, ensuring regulatory compliance, and optimizing production workflows to accelerate the company's drug candidates to clinical trials and eventual commercialization.
Career Progression
Prior to joining Rapport, Gregg held senior leadership roles at leading biotechnology companies, including Third Harmonic Bio and Cadent Therapeutics. As the Senior Vice President of Drug Discovery and Product Development at Third Harmonic Bio, he spearheaded the successful advancement of multiple drug candidates through preclinical and early-stage clinical development. Earlier in his career, he served as the Vice President of Product Development at Cadent Therapeutics, where he played a pivotal role in the transition of the company's lead asset from discovery to clinical evaluation.
Academic Background
Gregg holds a Ph.D. in Organic Chemistry from Yale University, where his research focused on the development of novel synthetic methodologies and the total synthesis of complex natural products. His strong academic foundation and technical expertise have been instrumental in his ability to navigate the complex challenges of drug development.
Areas of Expertise
- Chemistry, manufacturing, and controls (CMC) strategy and implementation
- Product development lifecycle management
- Regulatory compliance and quality assurance
- Cross-functional team leadership and coordination
- Pharmaceutical R&D and project management
Professional Impact
Throughout his career, Gregg has made significant contributions to the advancement of innovative therapeutics. He has successfully led multiple drug candidates through critical development stages, ensuring seamless transitions from preclinical to clinical phases. Notably, his work at Third Harmonic Bio resulted in the advancement of a lead asset to Phase 2 clinical trials, demonstrating his ability to drive impactful projects with measurable outcomes.
Conclusion
Gregg Keaney's extensive experience, technical expertise, and strategic leadership make him a valuable asset to Rapport Therapeutics. As the Senior Vice President of CMC and Product Development, he is poised to play a pivotal role in the company's efforts to develop and deliver transformative treatments to patients in need.
